Imatinib (STI571)

Catalog No.S2475 Synonyms: CGP057148B, ST-1571

Imatinib (STI571) Chemical Structure

Molecular Weight(MW): 493.6

Imatinib (STI571) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 46 Publications

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Imatinib (STI571) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
Targets
PDGFR [1]
(Cell-free assay)
c-Kit [2]
(M-07e cells)
v-Abl [1]
(Cell-free assay)
100 nM 100 nM 600 nM
In vitro

In vitro assays for inhibition of a panel of tyrosine and serine/threonine protein kinases show that Imatinib inhibits the v-Abl tyrosine kinase and PDGFR potently with an IC50 of 0.6 and 0.1 μM, respectively. [1] Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with a IC50 for these effects of approximately 0.1 μM, which is similar to the concentration required for inhibition of PDGFR. [2] Imatinib exhibits growth-inhibitory activity on the human bronchial carcinoid cell line NCI-H727 and the human pancreatic carcinoid cell line BON-1 with an IC50 of 32.4 and 32.8 μM, respectively. [3] A recent study shows that Imatinib has the potential to exert its antileukemia effects in chronic myelogenous leukemia by down-regulating hERG1 K(+) channels, which are highly expressed in leukemia cells and appear of exceptional importance in favoring leukemogenesis. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LAMA-84 MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvJWZNKSzVyPUCuNFc{ODRizszN NFvxfZdUSU6JRWK=
EM-2 NGrBNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEi4PEDPxE1? M4TBb3NCVkeHUh?=
MEG-01 M{HLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO3TWM2OD1yLkC4PVIyKM7:TR?= M3LpZXNCVkeHUh?=
BV-173 M1u3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT4TWM2OD1yLkG4O|Qh|ryP MkPRV2FPT0WU
K-562 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMkK0N|Ih|ryP NIP2dYpUSU6JRWK=
CGTH-W-1 NFzROYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwM{izO|Qh|ryP M2HPW3NCVkeHUh?=
ST486 M4WwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLnZW86UUN3ME2wMlY5PTRizszN MlmxV2FPT0WU
NCI-H1436 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTNTWM2OD1yLkm3PFAyKM7:TR?= MYXTRW5ITVJ?
NOS-1 MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PzdWlEPTB;MT62OVM5OyEQvF2= MUjTRW5ITVJ?
A498 M1rMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PwfmlEPTB;Mj61O|IzOyEQvF2= NEjxOm1USU6JRWK=
BE-13 M1;ROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJwNkKxNFYh|ryP MXTTRW5ITVJ?
SUP-T1 M3HRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDGPZhKSzVyPUOuPFI6ODdizszN M2q5fXNCVkeHUh?=
NCI-H1770 NHv2OXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvpOmE6UUN3ME21MlU4OjZ{IN88US=> MVnTRW5ITVJ?
IMR-5 NILFZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW1VoxKSzVyPU[uNlIyPDdizszN NFnFSIpUSU6JRWK=
LB2241-RCC MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfZbYxKSzVyPUiuNFc{QDRizszN M{n5SHNCVkeHUh?=
TGBC24TKB M2W1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRThwM{SwOVIh|ryP NESxZo9USU6JRWK=
SCC-15 M2n0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCxfYVyUUN3ME2xNE44Pzh6IN88US=> M4jUTHNCVkeHUh?=
BB49-HNC MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\tOnhnUUN3ME2xOE4{OzN3IN88US=> M2i5VHNCVkeHUh?=
ES7 NWj6O5ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHSU5RKSzVyPUG0Mlc{PzlizszN MmrXV2FPT0WU
LB2518-MEL M3e4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfsTWM2OD1zNj62NFk1KM7:TR?= M3zpfXNCVkeHUh?=
NCI-H510A MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;q[3lyUUN3ME2xO{4zPDR{IN88US=> M1LCSXNCVkeHUh?=
TE-441-T MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXETWM2OD1zNz6yPFg3KM7:TR?= Mmm2V2FPT0WU
HH M2XwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P1fWlEPTB;MUeuN|k6QSEQvF2= NH7Ld4RUSU6JRWK=
LC4-1 M3rSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr3[Y4xUUN3ME2xPE4xPjV{IN88US=> MYDTRW5ITVJ?
KARPAS-45 MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF6LkG4OFgh|ryP M2rGc3NCVkeHUh?=
LB1047-RCC Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LaZmlEPTB;MUiuOFQ2OiEQvF2= NVzDb4E5W0GQR1XS
NKM-1 MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF7LkO1OVIh|ryP NUXZTJh3W0GQR1XS
SCLC-21H M2PVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17sPGlEPTB;MkCuNVI1PiEQvF2= MX\TRW5ITVJ?
RS4-11 M3jVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJyLkOzNFgh|ryP M4HrcHNCVkeHUh?=
ALL-PO MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3X[ZVVUUN3ME2yNE45OTR7IN88US=> NVLVem1HW0GQR1XS
GDM-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ{LkW5OFUh|ryP M3H6V3NCVkeHUh?=
DMS-79 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfQTohvUUN3ME2yOE41QTN2IN88US=> M4PifnNCVkeHUh?=
MPP-89 M3vN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPBTWM2OD1{NT62PFc1KM7:TR?= MlnZV2FPT0WU
NB10 NV;T[FJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\2ZYg3UUN3ME2yOk41Pjl7IN88US=> MULTRW5ITVJ?
LS-513 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFixb4JKSzVyPUK2Mlg5PDdizszN Ml:4V2FPT0WU
L-540 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfIcItKSzVyPUK2MlkyPDNizszN NUDUWnMyW0GQR1XS
ES1 MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvyOmEzUUN3ME2yO{42OjFizszN NVjWfJV[W0GQR1XS
NTERA-S-cl-D1 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnNVmQ5UUN3ME2zNE42ODl|IN88US=> MmjjV2FPT0WU
EW-1 M3rIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTN{Lkm0OVQh|ryP MU\TRW5ITVJ?
Calu-6 NHLvT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XofmlEPTB;M{OuNVg2PSEQvF2= NH\3W3pUSU6JRWK=
CTV-1 M1fqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLhNJllUUN3ME2zN{46Pzh7IN88US=> NXuwTVlHW0GQR1XS
YT MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHBTWM2OD1|OD61NlA6KM7:TR?= NGTvZpRUSU6JRWK=
TE-6 M{XLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDPb2xvUUN3ME20NU4zPzl6IN88US=> M1\WZnNCVkeHUh?=
HT-144 NU\vRVdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTRzLkW0PFYh|ryP NXPQO5pRW0GQR1XS
EW-13 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVSyOHl1UUN3ME20Nk4zPzlzIN88US=> MkCyV2FPT0WU
KALS-1 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW3TWM2OD12Mz6xN|I6KM7:TR?= M2HHO3NCVkeHUh?=
MOLT-16 M4TS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXTTWM2OD12NT6wO|UzKM7:TR?= MWXTRW5ITVJ?
D-336MG MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[2cmlEPTB;NEWuPVU6QSEQvF2= MWrTRW5ITVJ?
TE-11 Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PhUWlEPTB;NE[uOlU{KM7:TR?= NV6yb5Z4W0GQR1XS
EB2 M1TCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTR4Lk[5PUDPxE1? M4Ps[nNCVkeHUh?=
SK-N-DZ M1LvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTR6LkC5OlEh|ryP MX3TRW5ITVJ?
SW684 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTR6LkK2PVUh|ryP NE[2eGtUSU6JRWK=
EW-18 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTHTWM2OD12OD60N|k2KM7:TR?= NWPlb2k3W0GQR1XS
RL95-2 MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\zc3FKSzVyPUWwMlA4OSEQvF2= NEnoSWhUSU6JRWK=
CHP-126 NVn3Z4l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTVyLki5NFUh|ryP MV7TRW5ITVJ?
NCI-H1395 NY\ofG9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHmTpZKSzVyPUWxMlc5OzVizszN MljsV2FPT0WU
TE-15 NWPvd4VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXGTWM2OD13Mj6yOVU3KM7:TR?= NHKzNJFUSU6JRWK=
ES4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\ofWlEPTB;NUKuPVc4PSEQvF2= M12yV3NCVkeHUh?=
TE-1 NYPQR21pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37KVGlEPTB;NUOuPVQ2PSEQvF2= M4fiN3NCVkeHUh?=
SIMA NXjoTI1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTV5LkOzNVEh|ryP MonCV2FPT0WU
LB647-SCLC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHFe2RKSzVyPU[0MlEyQDhizszN M3mxeHNCVkeHUh?=
KY821 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\sTWM2OD14ND6yOVUzKM7:TR?= MYXTRW5ITVJ?
LC-2-ad NX;HZ5UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHxdYZKSzVyPU[1Mlc3ODFizszN MV7TRW5ITVJ?
KP-N-RT-BM-1 NYrjV4VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq3TWM2OD14Nj62N|Y3KM7:TR?= Ml;JV2FPT0WU
SW872 M2D2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTZ5LkSzPFIh|ryP NUnoOpFGW0GQR1XS
ES5 NXqzdHlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXETmd{UUN3ME22O{43QTZ6IN88US=> NEG1PI9USU6JRWK=
SK-NEP-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml35TWM2OD14OD6zPFA{KM7:TR?= NUnwSmNSW0GQR1XS
RPMI-6666 M3;LZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK2OlBKSzVyPUexMlA{OiEQvF2= NFHxZmdUSU6JRWK=
UACC-812 NF;UepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm5TWM2OD15MT6xOlA6KM7:TR?= MoHLV2FPT0WU
COLO-829 NYPoVVdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnYOIZKSzVyPUeyMlY6QDdizszN NEflXGRUSU6JRWK=
KP-N-YS MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXyTWM2OD15Mj63NVM6KM7:TR?= MXHTRW5ITVJ?
GI-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTd|LkK4Olgh|ryP NEDQe3FUSU6JRWK=
ETK-1 NIfiOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTd|LkS5N|Ih|ryP M{j6enNCVkeHUh?=
LXF-289 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTd|LkeyPUDPxE1? MmruV2FPT0WU
CAS-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDqTWM2OD15Mz64PFU4KM7:TR?= MX7TRW5ITVJ?
EW-22 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTd2LkexNVUh|ryP MoO0V2FPT0WU
NCI-H2196 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe4N|BKSzVyPUe1MlY{PzlizszN NFy3NlJUSU6JRWK=
EoL-1-cell MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH5TWM2OD16MT62PVY{KM7:TR?= NXfXPZh1W0GQR1XS
D-247MG NXPVeYN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PrZ2lEPTB;OEKuNFI1QCEQvF2= Mn7yV2FPT0WU
Becker NVLVdpZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[3TWM2OD16Mj6zOFgyKM7:TR?= MVjTRW5ITVJ?
IST-MEL1 NXzDPZhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnOU4hKSzVyPUiyMlM1QDJizszN NYPVR5BzW0GQR1XS
MDA-MB-134-VI NIPFPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHLTWM2OD16Mj61PVk3KM7:TR?= M1rXTHNCVkeHUh?=
NCI-H1092 NFr3fm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3ITWM2OD16ND6wNVk4KM7:TR?= NFvpfG5USU6JRWK=
KINGS-1 NULWNpk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HaNWlEPTB;OE[uNVYyQCEQvF2= NEXr[2RUSU6JRWK=
HCC2218 NGLzb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTh4Lke5NVMh|ryP NFLT[5pUSU6JRWK=
GI-ME-N MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTh5Lke2PVkh|ryP NG\pTItUSU6JRWK=
AM-38 NUL3OlJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GzVGlEPTB;OEiuN|k2OyEQvF2= M4HKOnNCVkeHUh?=
KNS-42 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XxfmlEPTB;OEmuNVAyQCEQvF2= NIfFS|JUSU6JRWK=
C8166 NUjkVpZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn0XIx{UUN3ME24PU43OTJ3IN88US=> M{LRcnNCVkeHUh?=
Ramos-2G6-4C10 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\xTWM2OD16OT64O|E6KM7:TR?= NIX4WYhUSU6JRWK=
CTB-1 NHrTUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nrVGlEPTB;OUCuOlM2PyEQvF2= M2LUPXNCVkeHUh?=
HCE-4 NF\4UVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi3fGVKSzVyPUmxMlE{OzZizszN M4LWNXNCVkeHUh?=
NCI-H526 Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLaTWM2OD17Mj60NVA{KM7:TR?= NFrEV3VUSU6JRWK=
ECC4 M{\vcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrvZ4VYUUN3ME25OE4zPTV3IN88US=> MmjDV2FPT0WU
NCCIT MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln3TWM2OD17NT6zNlkzKM7:TR?= NXLZTmJrW0GQR1XS
MZ7-mel MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTl3LkmwOEDPxE1? NFHvcolUSU6JRWK=
COLO-684 M3LrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHYTWM2OD17Nj6yN|g2KM7:TR?= NWOyVnh{W0GQR1XS
SU-DHL-1 NUTT[IVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j6XGlEPTB;OU[uPVg1OiEQvF2= MlLGV2FPT0WU
SF126 M{m5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TSS2lEPTB;OUeuOVIyPyEQvF2= MmXqV2FPT0WU
NMC-G1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnzcFVKSzVyPUm4MlQ2PTRizszN MYjTRW5ITVJ?
NB14 NXnxVoc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXCRnpKSzVyPUm4MlkzODhizszN NXm5XIdKW0GQR1XS
VA-ES-BJ MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL5cHpKSzVyPUm5MlQxPTZizszN NHiwbYlUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Imatinib produces a different antitumor effect on three xenografted tumors derived from surgical samples of fresh human small cell lung cancers, with 80%, 40% and 78% growth inhibition of SCLC6, SCLC61 and SCLC108 tumors, respectively, and no significant inhibition of SCLC74 growth. [5] In high fat fed ApoE(-/-) mice, Imatinib significantly reduces the high fat-induced lipid staining area by 30%, 27% and 35% compared to high-fat diet untreated controls when dosed by gavage at 10, 20 and 40 mg/kg, respectively, and suppresses carotid artery lipid accumulation. [6]

Protocol

Kinase Assay:

[1]

+ Expand

PDGF receptor kinase activity:

PDGF receptor is immunoprecipitated from BALB/c 3T3 cell extracts with rabbit antiserum to the murine PDGF receptor for 2 hours on ice. Protein A-Sepharose beads are used to collect the antigen-antibody complexes. The immunoprecipitates are washed twice with TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), once with TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and once with kinase buffer (20 mM Tris, pH 7.5,10 mM MgCl2). After stimulation with PDGF (50 ng/mL) for 10 minutes at 4 °C, different concentrations of drug are added to the reaction mixture. PDGF receptor kinase activity is determined by incubation with 10 μCi [7-33P]-ATP and l μM ATP for 10 minutes at 4 °C. Immune complexes are separated by SDS-PAGE on 7.5% gels.
Cell Research:

[3]

+ Expand
  • Cell lines: BON-1 cells and NCI-H727 cells
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method:

    BON-1 cells and NCI-H727 cells are seeded into flat-bottomed 96-well plates in triplicate and allowed to adhere overnight in 10% fetal bovine serum-supplemented DMEM or RPMI 1640 complete medium, respectively; the medium is then exchanged for serum-free medium (negative control) or serum-free medium containing serial dilutions of Imatinib. After 48 hours (control cultures do not reach confluence), the number of metabolically active cells is determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and absorbance is measured in a Packard Spectra microplate reader at 540 nm. Growth inhibition is calculated using the following formula: inhibition rate = (1 − a / b) × 100%, where a and b are the absorbance values of the treated and control groups, respectively.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: SCLC6, SCLC61, SCLC 74 and SCLC108 small cell lung cancers are injected into Swiss mice (nu/nu, female).
  • Formulation: Imatinib is diluted in water.
  • Dosages: 70 or 100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (66.85 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 493.6
Formula

C29H31N7O

CAS No. 152459-95-5
Storage powder
in solvent
Synonyms CGP057148B, ST-1571

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03862768 Not yet recruiting Gastrointestinal Stromal Tumors|Surgery Shanghai Zhongshan Hospital July 2019 Not Applicable
NCT03862768 Not yet recruiting Gastrointestinal Stromal Tumors|Surgery Shanghai Zhongshan Hospital July 2019 Not Applicable
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03802084 Not yet recruiting Desmoid Tumor Yonsei University April 2019 Phase 1|Phase 2
NCT03802084 Not yet recruiting Desmoid Tumor Yonsei University April 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you please advise whether it is a clear solution for compound dissolved in vehicle 2% DMSO+30% PEG 300+2% Tween 80+ddH2O?

  • Answer:

    For S2475 Imatinib (STI571), it is soluble in 2% DMSO+30% PEG 300+2% Tween 80+ddH2O at 2mg/ml. When making the solution, please dissolve the compound in DMSO clearly first. If it dissolves not readily, please sonicate and warm it in water bath at 45-50C. Then add PEG and Tween. After they mixed well, dilute with water.

  • Question 2:

    What is the difference between S2475 (Imatinib) and S1026 (Imatinib Mesylate)? Are they water soluble?

  • Answer:

    S2475 is free base of Imatinib while S1026 is a solt form of Imatinib. They have exactly the same biological activity but different solubility. S1026 can be dissolved in water, but S2475 is not soluble in water. S2475 can be dissolved in DMSO at up to 3mg/ml.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products5

Tags: buy Imatinib (STI571) | Imatinib (STI571) supplier | purchase Imatinib (STI571) | Imatinib (STI571) cost | Imatinib (STI571) manufacturer | order Imatinib (STI571) | Imatinib (STI571) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID